Bisphosphonate treatment maintains positive effect on bone loss at 6 year follow-up .
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty
J Orthop Res. 2009 Feb;27(2):183-849 patients who had undergone total hip arthroplasty (THA) were randomized to a postoperative bisphosphonate (oral alendronate) treatment group or to a non-treatment group, to assess the effect of bisphosphonate on bone mineral density (BMD) and bone loss. Results from this study indicated that there was a significant increase in BMD from the 1-year to the 6-year follow up in Gruen region 5 of the control group and Gruen region 6 of the 20 mg alendronate subgroup. There were no differences in BMD values from the 1-year to the 6-year follow-up in every other Gruen region for all groups, maintaining the positive effects of the 1-year follow-up. Lastly, there was no difference in clinical outcomes between the treatment and control groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
